PDF(Pubmed)
Abstract：
UNASSIGNED: There is little evidence on the effects of antipsychotic polypharmacy on metabolic parameters in patients with schizophrenia. Thus, this cross-sectional study explored the associations between the number of antipsychotics prescribed and metabolic parameters in Japanese patients with schizophrenia.
UNASSIGNED: We obtained metabolic parameter data from 19,675 patients with schizophrenia. Of these, 1380 (7.0%), 8422 (42.8%), 6326 (32.2%), and 3547 (18.0%) were treated with none, one, two, and three or more antipsychotics, respectively. We compared eight metabolic parameters among the four groups using univariate analyses. We then performed multiple regression analysis to assess the effect of the number of antipsychotics prescribed on metabolic parameters after controlling for the effects of age, sex, type of care (outpatient/inpatient), chlorpromazine-equivalent dose, and antipsychotic type (aripiprazole, olanzapine, and risperidone).
UNASSIGNED: There were significant differences in body mass index (BMI), systolic and diastolic blood pressure (dBP), total cholesterol, low-density lipoprotein cholesterol, and triglycerides among the four groups. The multiple regression analysis showed that the number of antipsychotics prescribed was significantly correlated with BMI and dBP (standardized regression coefficient = 0.031 and 0.026, respectively).
UNASSIGNED: Our results suggested that the number of antipsychotics prescribed adversely affects BMI and dBP. Clinicians should avoid inappropriate antipsychotic polypharmacy, especially polypharmacy involving three or more antipsychotics.
UNASSIGNED: We obtained metabolic parameter data from 19,675 patients with schizophrenia. Of these, 1380 (7.0%), 8422 (42.8%), 6326 (32.2%), and 3547 (18.0%) were treated with none, one, two, and three or more antipsychotics, respectively. We compared eight metabolic parameters among the four groups using univariate analyses. We then performed multiple regression analysis to assess the effect of the number of antipsychotics prescribed on metabolic parameters after controlling for the effects of age, sex, type of care (outpatient/inpatient), chlorpromazine-equivalent dose, and antipsychotic type (aripiprazole, olanzapine, and risperidone).
UNASSIGNED: There were significant differences in body mass index (BMI), systolic and diastolic blood pressure (dBP), total cholesterol, low-density lipoprotein cholesterol, and triglycerides among the four groups. The multiple regression analysis showed that the number of antipsychotics prescribed was significantly correlated with BMI and dBP (standardized regression coefficient = 0.031 and 0.026, respectively).
UNASSIGNED: Our results suggested that the number of antipsychotics prescribed adversely affects BMI and dBP. Clinicians should avoid inappropriate antipsychotic polypharmacy, especially polypharmacy involving three or more antipsychotics.
摘要：
■几乎没有证据表明抗精神病药物复方对精神分裂症患者代谢参数的影响。因此，这项横断面研究探讨了日本精神分裂症患者的抗精神病药处方数量与代谢参数之间的关联.
■我们获得了19,675名精神分裂症患者的代谢参数数据。其中,1380（7.0%），8422（42.8%），6326（32.2%），3547例（18.0%）无治疗，一,两个,和三种或三种以上的抗精神病药物，分别。我们使用单变量分析比较了四组中的八个代谢参数。然后，我们进行了多元回归分析，以评估在控制年龄的影响后，处方抗精神病药的数量对代谢参数的影响。性别,护理类型(门诊/住院)，氯丙嗪-等效剂量，和抗精神病药物类型(阿立哌唑，奥氮平,和利培酮)。
■体重指数（BMI）存在显着差异，收缩压和舒张压（dBP），总胆固醇,低密度脂蛋白胆固醇，四组中的甘油三酯。多元回归分析显示，抗精神病药的处方数量与BMI和dBP显着相关（标准化回归系数分别为0.031和0.026）。
■我们的结果表明，处方抗精神病药的数量会对BMI和dBP产生不利影响。临床医生应避免使用不适当的抗精神病药物，特别是涉及三种或三种以上抗精神病药的多重用药。
■我们获得了19,675名精神分裂症患者的代谢参数数据。其中,1380（7.0%），8422（42.8%），6326（32.2%），3547例（18.0%）无治疗，一,两个,和三种或三种以上的抗精神病药物，分别。我们使用单变量分析比较了四组中的八个代谢参数。然后，我们进行了多元回归分析，以评估在控制年龄的影响后，处方抗精神病药的数量对代谢参数的影响。性别,护理类型(门诊/住院)，氯丙嗪-等效剂量，和抗精神病药物类型(阿立哌唑，奥氮平,和利培酮)。
■体重指数（BMI）存在显着差异，收缩压和舒张压（dBP），总胆固醇,低密度脂蛋白胆固醇，四组中的甘油三酯。多元回归分析显示，抗精神病药的处方数量与BMI和dBP显着相关（标准化回归系数分别为0.031和0.026）。
■我们的结果表明，处方抗精神病药的数量会对BMI和dBP产生不利影响。临床医生应避免使用不适当的抗精神病药物，特别是涉及三种或三种以上抗精神病药的多重用药。
